

Revance Therapeutics Investor Relations Department 7555 Gateway Boulevard Newark, CA 94560 United States

Visit IR website ☐ Sign-up for Email alerts ☐

22.90
4:00 PM ET Jul 27, 2017
0.00 (0.000%)
N/A - N/A
12.35 - 28.30
N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... (more)

Stock Performance



Press Releases [View all]

Jul 24, 2017

Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017

Jun 15, 2017

Positive BELMONT Phase 2 Trial Results
Published in Dermatologic Surgery

Jun 5, 2017

Revance Reports Additional Positive Week
24 Efficacy Results from RT002 Injectable
Phase 2 Cervical Dystonia Trial

Jun 1, 2017

Revance to Participate in Upcoming Investor Conferences

May 18, 2017

Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial

Upcoming Events [View all]

Aug 3, 2017 4:30 PM ET
Revance Therapeutics 2017 Second Quarter
Financial Results

Financials [View all]

First Quarter Financial Results

Feb 28, 2017 Annual Report (10-K)

Mar 24, 2017 Proxy Statement (DEF 14A)

May 9, 2017

Quarterly Report (10-Q)

Nov 4, 2016

Quarterly Report (10-Q)

Aug 5, 2016

Quarterly Report (10-Q)